Introduction {#S0001}
============

Intracranial myeloid sarcoma is a very rare disease presenting with or without bone marrow involvement[@CIT0001]. The optimal treatment remains unknown. Conventional acute myeloid leukemia (AML) -like chemotherapy, radiotherapy, and surgery are the currently recommended strategies in controlling the disease progress[@CIT0002]. However, the optimal treatment for intracranial myeloid sarcoma remains unknown. In this paper we report a case of successful rescue of intracranial myeloid sarcoma with acute intracranial hypertension through intensified induction chemotherapy of idarubicin (12mg/m^2^·d×3 days) combined with high-dose cytarabine (2g/m^2^ q12h×3 days), and we also did a literature review of the published data of intracranial myeloid sarcoma, which mainly focuses on how to choose the optimal treatment for such patients.

Case Presentation {#S0002}
=================

A 28-year-old male patient was admitted to the hematological department at our hospital in June 2017, with a 4-day history of intense headache, worsening blurred vision and severe vomiting. The patient had a history of neurosurgical operation with resection of tumor involving the regions of torcular herophili and left transverse sinus in April 2017. The pathological findings of the tumor specimen led to a diagnosis of intracranial myeloid sarcoma. Preoperative magnetic resonance imaging (MRI) ([Figure 1](#F0001){ref-type="fig"}) and Postoperative cranial computed tomography (CT) indicated complete resection of the lesion ([[Supplement Figures 1](https://www.dovepress.com/get_supplementary_file.php?f=230478.docx)]{.ul} and [[2](https://www.dovepress.com/get_supplementary_file.php?f=230478.docx)]{.ul}). A diagnostic lumbar puncture showed no malignant cells, and methotrexate 10mg, cytarabine 50 mg and dexamethasone 5mg were given intrathecally. Bone marrow aspirate and biopsy had been conducted in May 2017, which demonstrated 5.5% blasts expressing CD13, CD33, CD34, CD117 and MPO, and the cytogenetic analysis demonstrated t(8;21)(q22;q22), and molecular studies showed a positive RUNX1-RUNX1T1 rearrangement, but negative for c-KIT, FLT3, NPM1, or CEBPA mutations. The diagnosis of AML with t (8; 21) (q22; q22)/RUNX1-RUNX1T1 was made. However, the patient refused to receive any systemic chemotherapy.Figure 1The MRI of incipient intracranial myeloid sarcoma of the patient before operation. In the left occipital region, there was a kind of circular broad base with slightly longer T1 and short T2 signal shadow, with clear boundary and a size of about 23x37mm. The internal signal was uniform, which was enhanced uniformly.

Headache appeared on 60-day after the surgical operation, and aggravated gradually, accompanied by blurred vision and severe vomiting. Blood routine was normal at admission. After admission, the emergency cranial CT indicated a circular hyperdense mass (54mm×37mm), which was surrounded by hypodense peritumoral edema in the left cerebellar hemisphere, and the density of the lesions was uniform and the margin was clear ([Figure 2A](#F0002){ref-type="fig"}).Figure 2Recurrent intracranial myeloid sarcoma before and after chemotherapy. The emergency cranial CT demonstrated a circular hyperdense mass (54mm×37mm) in the left cerebellar hemisphere at the admission (**A**). Cranial CT indicated that the mass was markedly reduced (20mm×15mm) on the first day after chemotherapy (**B**), and the mass was completely disappeared on the sixth day after chemotherapy (**C**).

The recurrence of intracranial myeloid sarcoma was considered. The patient could die at any time due to acute intracranial hypertension. He refused decompressive craniectomy and emergency cranial radiotherapy to alleviate the symptoms. Idarubicin (12mg/m^2^.d×3 days) combined with high-dose cytarabine (2g/m^2^.q12h×3 days) was initiated for emergency chemotherapy. Mannitol and valproate were used to reduce intracranial pressure and prevent seizures.

Chemotherapy was very effective. On the second day of chemotherapy, the symptoms of headache were obviously relieved, the number of vomiting was reduced, and the vision gradually became clear. All of the above symptoms disappeared at the end of chemotherapy. On the first day after chemotherapy, the cranial CT indicated that the cranial lesion was markedly reduced (20mm×15mm) ([Figure 2B](#F0002){ref-type="fig"}), and on the sixth day after chemotherapy, the lesion was completely disappeared ([Figure 2C](#F0002){ref-type="fig"}). The patient experienced 12 days of severe neutropenia. With the support of granulocyte colony stimulating factor (G-CSF), the patient recovered with normal neutrophil on the fourteenth day after chemotherapy. Then the patient received 2 courses of high-dose cytarabine (3g/m^2^.q12h×3 days) with normal cranial MRI and without any CNS symptoms. Bone marrow aspiration showed morphology complete remission with normal cytogenetics and negative RUNX1-RUNX1T1 arrangement. However, the patient had a very poor compliance and refused any form of medical service after that. And now, the patient has been lost to follow-up.

Discussion and Literature Review {#S0003}
================================

Intracranial myeloid sarcomas are rare and account for about 3% of all extramedullary sarcomas. Myeloid sarcoma can be caused by AML,[@CIT0003] chronic myeloid leukemia (CML),[@CIT0004],[@CIT0005] chronic myelomonocytic leukemia (CMML),[@CIT0006] and primary myelofibrosis (PMF).[@CIT0007]--[@CIT0009] It has been reported that intracranial myeloid sarcoma may originate from the superficial arachnoid vein wall and extend into the cerebrospinal fluid. The expanded leukemic mass infiltrates into the brain parenchyma through the cortical glial membrane and eventually forms intracerebral tumor. The most common clinical manifestations of intracranial myeloid sarcoma are headache, accompanied by numbness of limbs, blurred vision, epilepsy, etc. Common intracranial myeloid sarcoma gene mutation is t (8; 21),[@CIT0010] which is the same as our case. Some others are t (15; 17) as in literature.[@CIT0011] The misdiagnosis rate of myeloid sarcoma is relatively high. Imaging methods such as CT and MRI can improve the diagnosis and facilitate early treatment, but the definite diagnosis was dependent on the pathology and immunohistochemistry of mass biopsy or surgical specimen. It has been reported that MRI can effectively evaluate the lesion status and treatment effect.

The overall prognosis for extramedullary myeloid sarcoma is poor, with an average survival time of 2.5 to 22 months. Currently, there is no clear or uniform international guideline for this kind of disease. According to the existing literature, most cases are treated with a combination of surgical resection, chemotherapy and/or radiotherapy. Surgical resection and radiotherapy alone do not prevent disease recurrence and progression, therefore, do not prolonged the long-term survival.[@CIT0012] It has been reported in the literature that intensive chemotherapy regimens, which include anthracyclines and high-dose cytarabine, can certainly improve the survival rate of patients. Hematopoietic stem cell transplantation may be an effective method to improve the long-term survival rate of myeloid sarcoma, especially when patients reach complete remission after intensive chemotherapy.[@CIT0013] In our case, chemotherapy achieved the same effect as surgical excision. Similar treatment regimens for subsequent cases are listed in [[supplement table 1](https://www.dovepress.com/get_supplementary_file.php?f=230478.docx)]{.ul}. From which it can be seen that all cases were treated with chemotherapy-based approaches for myeloid sarcoma, and the prognosis of the patients was relatively good. The most common causes of death for myeloid sarcomas are infection, postoperative bleeding, and hernia of the brain due to the short-term enlargement of the tumor. Chemotherapy is as effective as surgical excision, especially with High-dose cytarabine that can penetrate the blood-brain barrier.

In this reported case, the patient had a recurrence of AML related intracranial myeloid sarcoma. Severe intracranial hypertension was present at the time of admission, and cerebral hernia might occur at any time and lead to death. The patient refused decompressive craniectomy and emergency cranial radiotherapy to alleviate the symptoms. So, chemotherapy, as the current preferred treatment for AML induction, idarubicin (12mg/m^2^.d×3 days) combined with high-dose cytarabine (2g/m^2^ q12h×3 days) was initiated for emergency chemotherapy. The lipophilic idarubicin and high-dose cytarabine both can quickly pass through the blood-brain barrier, and penetrate into tumor cells and dissolve tumor cells, thus effectively control the progression of the disease. The use of this combination did not result in a long-term myelosuppression, potentially life-threatening infections and bleeding, and excessive hospital costs or prolonged hospital stays.

Conclusion {#S0004}
==========

Intracranial myeloid sarcoma is a rare disease with poor prognosis. Currently, there are no clear guidelines for the treatment of relevant diseases. The standard dose of idarubicin (12mg/m^2^·d×3 days) and high-dose cytarabine (2--3g/m^2^.q12h×3 days) both can pass through the blood-brain barrier, thus effectively controlling the progression of the disease without severe complications. Our patient's treatment approach could provide a reference for this disease with such emergency situation.
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